Research Article 
Amyloid imaging in dementias with atypical presentation
David A. Wolk, Julie C. Price, Charles Madeira, Judy A. Saxton, Beth E. Snitz, Oscar L. Lopez, Chester A. Mathis, William E. Klunk and Steven T. mailto:[email protected]:[email protected]
Alzheimer`s & Dementia, 2012, 8(5), 389-398. DOI: 10.1016/j.jalz.2011.07.003
Abstract
Background With the potential emergence of disease specific therapies, an accurate biomarker of Alzheimer‘s Disease pathology is needed in cases in which the underlying etiology is uncertain. We explored the potential value of amyloid imaging in patients with atypical presentations of dementia. Methods Twenty-eight patients with atypical dementia underwent positron emission tomography imaging with the amyloid imaging tracer Pittsburgh compound B (PiB). Twenty-six had [18F]fluoro-2-deoxy-D-glucose positron emission tomography scans. After extensive clinical evaluation, this group of patients generated considerable diagnostic uncertainty and received working diagnoses that included possible Alzheimer‘s disease (AD), focal dementias (e.g., posterior cortical atrophy [PCA]), or cases in which no clear diagnostic category could be determined (dementia of uncertain etiology). Patients were classified as PiB-positive, PiB-negative, or PiB-intermediate, based on objective criteria. Anterior–posterior and left–right indices of PiB and [18F]fluoro-2-deoxy-D-glucose uptake were calculated to examine differences in distribution of amyloid pathology and metabolic changes associated with clinical phenotype. Results Eleven patients (39%) were PiB positive, 16 were PiB negative (57%), and one (4%) was PiB intermediate. By diagnostic category, three of 10 patients (30%) with dementia of uncertain etiology, one of five (20%) with primary progressive aphasia, three of five (60%) with PCA, and four of seven (57%) with possible AD were PiB positive. Brain metabolism of both PiB-positive and PiB-negative patients was generally similar by phenotype, but appeared to differ from typical AD. PCA patients also appeared to differ in their relative distribution of PiB compared with typical AD, consistent with their atypical phenotype. Conclusions AD pathology is frequently present in atypical presentations of dementia and can be identified by amyloid imaging. Clinical phenotype is more related to the pattern of cerebral hypometabolism than the presence/absence of amyloid pathology. These findings have diagnostic, prognostic, and therapeutic implications.
ASCI-ID: 285-210
Similar Articles
A European perspective on population studies of dementia
Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloidAlzheimer`s & Dementia, 2011, 7(2), 133-141. DOI: 10.1016/j.jalz.2010.08.230
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer`s & Dementia, 2011, 7(3), 257-262. DOI: 10.1016/j.jalz.2011.03.004
The Alzheimer‘s Association external quality control program for cerebrospinal fluid biomarkersAlzheimer`s & Dementia, 2011, 7(4), 386-395. DOI: 10.1016/j.jalz.2011.05.2243
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumabAlzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353
Extended results of the Alzheimer‘s disease anti-inflammatory prevention trialAlzheimer`s & Dementia, 2011, 7(4), 402-411. DOI: 10.1016/j.jalz.2010.12.014
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 425-435. DOI: 10.1016/j.jalz.2010.09.003
Intracranial atherosclerosis as a contributing factor to Alzheimer‘s disease dementiaAlzheimer`s & Dementia, 2011, 7(4), 436-444. DOI: 10.1016/j.jalz.2010.08.228
Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 445-455. DOI: 10.1016/j.jalz.2010.09.002
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ɛ3/ɛ3 genotypeAlzheimer`s & Dementia, 2011, 7(4), 456-465. DOI: 10.1016/j.jalz.2010.11.012
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalusAlzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008
Long-term progression of Alzheimer‘s disease in patients under antidementia drugsAlzheimer`s & Dementia, 2011, 7(6), 579-592. DOI: 10.1016/j.jalz.2011.02.009
The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scalesAlzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trialsAlzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005
An economic evaluation of early assessment for Alzheimer‘s disease in the United KingdomAlzheimer`s & Dementia, 2012, 8(1), 22-30. DOI: 10.1016/j.jalz.2010.07.001
Modeling Alzheimer‘s disease progression using the disease system analysis approachAlzheimer`s & Dementia, 2012, 8(1), 39-50. DOI: 10.1016/j.jalz.2010.12.012
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization InitiativeAlzheimer`s & Dementia, 2012, 8(1), 65-73. DOI: 10.1016/j.jalz.2011.07.004
[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodiesAlzheimer`s & Dementia, 2012, 8(1), 74-83. DOI: 10.1016/j.jalz.2011.08.003
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006
Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 211-218. DOI: 10.1016/j.jalz.2011.04.008
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012
Alzheimer‘s disease: Pathogenesis and preventionAlzheimer`s & Dementia, 2012, 8(3), 227-233. DOI: 10.1016/j.jalz.2012.01.011
The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trialsAlzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
Safety and biomarker effects of solanezumab in patients with Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(4), 261-271. DOI: 10.1016/j.jalz.2011.09.224
Leptin and dementia over 32 years–The Prospective Population Study of WomenAlzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411
Gaining precision on the Alzheimer‘s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scoresAlzheimer`s & Dementia, 2012, 8(4), 288-294. DOI: 10.1016/j.jalz.2011.05.2409
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
Worldwide Alzheimer‘s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2012, 8(4), 337-342. DOI: 10.1016/j.jalz.2012.04.007
Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathologyAlzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408
Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ɛ4 carriersAlzheimer`s & Dementia, 2012, 8(4), 352-356. DOI: 10.1016/j.jalz.2011.04.010
Common Alzheimer‘s Disease Research Ontology: National Institute on Aging and Alzheimer‘s Association Collaborative ProjectAlzheimer`s & Dementia, 2012, 8(4), 372-375. DOI: 10.1016/j.jalz.2012.05.2115
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingAlzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesAlzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound BAlzheimer`s & Dementia, 2012, 8(6), 496-501. DOI: mailto:[email protected]
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smokingAlzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006
Differential prediction of vascular dementia and Alzheimer‘s disease in nondemented older adults within 5 years of initial testingAlzheimer`s & Dementia, 2012, 8(6), 528-535. DOI: 10.1016/j.jalz.2011.09.233
A new informant-based questionnaire for instrumental activities of daily living in dementiaAlzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006
Comparison of International Working Group criteria and National Institute on Aging�Alzheimer‘s Association criteria for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(6), 560-563. DOI: 10.1016/j.jalz.2011.10.008
Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokersAlzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231
The worldwide economic impact of dementia 2010Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006
Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ StudyAlzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer‘s disease and related disordersAlzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002
The economics of mild cognitive impairmentAlzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on AgingAlzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223
Intracerebral propagation of Alzheimer‘s disease: Strengthening evidence of a herpes simplex virus etiologyAlzheimer`s & Dementia, 2013, 9(2), 169-175. DOI: 10.1016/j.jalz.2012.07.005
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's diseaseAlzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006
Effectiveness of antidementia drugs in delaying Alzheimer's disease progressionAlzheimer`s & Dementia, 2013, 9(3), 338-345. DOI: 10.1016/j.jalz.2012.01.002
Risk disclosure and preclinical Alzheimer‘s disease clinical trial enrollmentAlzheimer`s & Dementia, 2013, 9(3), 356-359. DOI: 10.1016/j.jalz.2012.03.001
β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tauAlzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015
The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography coreAlzheimer`s & Dementia, 2010, 6(3), 221-229. DOI: 10.1016/j.jalz.2010.03.003
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloidAlzheimer`s & Dementia, 2011, 7(2), 133-141. DOI: 10.1016/j.jalz.2010.08.230
Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2013, 9(3), 295-301. DOI: 10.1016/j.jalz.2012.01.006
The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography coreAlzheimer`s & Dementia, 2010, 6(3), 221-229. DOI: 10.1016/j.jalz.2010.03.003
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 yearsAlzheimer`s & Dementia, 2010, 6(4), 326-333. DOI: 10.1016/j.jalz.2009.09.005
White matter integrity and cortical metabolic associations in aging and dementiaAlzheimer`s & Dementia, 2010, 6(1), 54-62. DOI: 10.1016/j.jalz.2009.04.1228
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2013, 9(3), 295-301. DOI: 10.1016/j.jalz.2012.01.006
Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2012, 8(6), 483-489. DOI: 10.1016/j.jalz.2011.08.008
Global gray matter changes in posterior cortical atrophy: A serial imaging studyAlzheimer`s & Dementia, 2012, 8(6), 502-512. DOI: 10.1016/j.jalz.2011.09.225